Kringle Pharma News

KRINGLE PHARMA: Notice regarding completion of exercise of stock acquisition rights with exercise price amendment clauses and monthly exercise status

May 27 23:20

KRINGLE PHARMA: Notice Concerning Mass Exercise of Stock Acquisition Rights with Exercise Price Amendment Clause

May 27 01:00

KRINGLE PHARMA: [Delayed] Financial results for the six months ended 2024/3/31 [Japanese GAAP] (unconsolidated)

May 22 21:30

KRINGLE PHARMA: Notice of publication of a transcript of the financial results briefing for the 2nd quarter of the fiscal year ending 2024/9 Logme Finance

May 21 21:30

KRINGLE PHARMA: Notice of determination of generic names for HGF pharmaceuticals in Japan

May 21 01:00

KRINGLE PHARMA: Q&A session on financial results briefing for the 2nd quarter of the fiscal year ending September 2024

May 20 02:20

KRINGLE PHARMA: Notice of video posting of financial results briefing for the 2nd quarter of the fiscal year ending September 2024

May 17 04:15

KRINGLE PHARMA: Financial results briefing materials for the 2nd quarter of the fiscal year ending 2024/9

May 17 02:00

KRINGLE PHARMA: Addition of clinical trial implementation facilities (Sanno Medical Center) to phase III clinical trials of HGF (hepatocyte growth factor) for vocal cord scars

May 16 01:10

KRINGLE PHARMA: Summary of financial results for the 2nd quarter of the fiscal year ending September 2024 [Japanese GAAP] (unconsolidated)

May 13 01:40

KRINGLE PHARMA: Quarterly Report - 23rd Quarter 2nd Quarter (2024/01/01 to 2024/03/31)

May 13 01:40

KRINGLE PHARMA: Confirmation letter

May 13 01:40

KRINGLE PHARMA: A review article on the development of HGF therapeutics for central nervous system diseases such as ALS was published in the journal “Pharmacia”

May 1 02:30

KRINGLE PHARMA: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clause

Apr 30 21:30

KRINGLE PHARMA: Joint research with Gifu University on applied research on HGF (hepatocyte growth factor) to idiopathic femoral head necrosis

Apr 30 02:30

KRINGLE PHARMA: Notice regarding the 2023 grant amount decision for rare disease drug testing research grants for development costs of recombinant human HGF proteins targeting acute spinal cord injury

Apr 25 21:30

KRINGLE PHARMA: (Correction) Partial correction to “Notice of holding financial results briefings and live streaming (Zoom webinar)”

Apr 23 01:05

KRINGLE PHARMA: Announcement of financial results briefings and live streaming (Zoom webinars)

Apr 22 21:30

KRINGLE PHARMA: Notice of provision of collateral in connection with the AMED CiCle business agreement

Apr 22 01:00

KRINGLE PHARMA: Notice of commencement of joint research with Tohoku University on additional analysis of phase II clinical trials (physician-led clinical trials) targeting ALS

Apr 18 18:50